A Phase 1 interventional study of TAK-653 and Placebo in Healthy Volunteers, sponsored by Neurocrine Biosciences. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.
The drug being tested in this study is called TAK-653. This study is designed to evaluate the central pharmacodynamic activity of TAK-653 using TMS. The study will enroll approximately 24 participants to yield 22 participants that complete treatment periods 1, 2, and 3. Participants will be randomly assigned to 1 of the 6 sequences to receive TAK-653 0.5 mg low dose or TAK-653 6 mg high dose or Placebo in double-blind treatment periods 1, 2, and 3, followed by Ketamine 0.5 mg/kg in open-label Treatment period 4.
All participants will receive one dose of TAK-653 (0.5 or 6 mg), or Placebo or Ketamine on Day 1 of each treatment period.
This single center trial will be conducted in the Netherlands. The overall time to participate in this study is 15 weeks. Participants will make 5 visits to the clinic. A washout period of minimum 10 days will be maintained between the doses in treatment periods 1 to 3. Follow-up phone call will be made on Day 14.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
Drug: TAK-653 · Drug: Placebo · Drug: Ketamine
Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5 Hours Post TAK-653 Dose
TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120 percent (%) of baseline resting motor threshold (rMT). rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 versus (vs.) matched oral placebo.
Time frame: Baseline, 2.5 hours post TAK-653 dose
Change From Baseline in Resting Motor Threshold (rMT) Obtained With Single-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
Time frame: Baseline, 2.5 hours post TAK-653 dose
Change From Baseline in Magnitude of Long Intracortical Inhibition (LICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
LICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in LICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
Time frame: Baseline, 2.5 hours post TAK-653 dose
Change From Baseline in Magnitude of Short Intracortical Inhibition (SICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
SICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse 80% of baseline rMT and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in SICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
Time frame: Baseline, 2.5 hours post TAK-653 dose
Change From Baseline in rMT Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post-dose of Ketamine
The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg/kg Ketamine.
Time frame: Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose
Change From Baseline in in Peak-to-Peak Amplitude of MEP Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post Dose of Ketamine
TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment 0.5 mg/kg Ketamine.
Time frame: Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose
Participants took part in the study at 1 investigative site in Netherlands from 11 February 2019 to 18 June 2019.
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 3 | 4 | 3 | 2 | 4 | 4 |
| Not completed | 1 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg | Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg | TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg | TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg | TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 2 | 4 | 4 |
| Completed | 2 | 4 | 3 | 2 | 4 | 4 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 |
TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120 percent (%) of baseline resting motor threshold (rMT). rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 versus (vs.) matched oral placebo.
| microvolt (mcV) | Placebo | TAK-653 0.5 mg | TAK-653 6 mg |
|---|---|---|---|
| Baseline | 898.828 ± 693.1535 | 841.068 ± 591.1367 | 1004.127 ± 574.5982 |
| Change at 2.5 Hours Post TAK-653 Dose | -139.117 ± 829.5901 | 17.265 ± 466.2556 | 139.932 ± 813.9705 |
The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
| percentage of maximum stimulator output | Placebo | TAK-653 0.5 mg | TAK-653 6 mg |
|---|---|---|---|
| Baseline | 55.3 ± 7.46 | 55.9 ± 8.99 | 55.3 ± 8.93 |
| Change at 2.5 hours post TAK-653 Dose | -0.1 ± 2.74 | -0.5 ± 1.74 | -0.3 ± 1.95 |
LICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in LICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
| percent inhibition | Placebo | TAK-653 0.5 mg | TAK-653 6 mg |
|---|---|---|---|
| Baseline: LICI 50 ms | 75.113 ± 97.2865 | 96.515 ± 113.2728 | 96.568 ± 111.1657 |
| Change at 2.5 Hours Post TAK-653 Dose: LICI 50 ms | 0.675 ± 54.5725 | 18.319 ± 81.4378 | 19.395 ± 110.0870 |
| Baseline: LICI 100 ms | 16.167 ± 27.0976 | 10.430 ± 14.1289 | 46.808 ± 149.9806 |
| Change at 2.5 Hours Post TAK-653 Dose: LICI 100 ms | 0.147 ± 29.1567 | 5.905 ± 18.8939 | -28.644 ± 142.5618 |
| Baseline: LICI 200 ms | 48.149 ± 33.1815 | 48.934 ± 48.6073 | 49.773 ± 37.7173 |
| Change at 2.5 Hours Post TAK-653 Dose: LICI 200 ms | 2.882 ± 21.2459 | 9.902 ± 42.5761 | 11.540 ± 30.1594 |
| Baseline: LICI 300 ms | 59.463 ± 31.1596 | 56.115 ± 36.8452 | 54.572 ± 30.5543 |
| Change at 2.5 Hours Post TAK-653 Dose: LICI 300 ms | -9.996 ± 27.7151 | 8.618 ± 36.0453 | 1.638 ± 32.6843 |
SICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse 80% of baseline rMT and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in SICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.
| percent inhibition | Placebo | TAK-653 0.5 mg | TAK-653 6 mg |
|---|---|---|---|
| Baseline: SICI 2 ms | 43.095 ± 30.7011 | 39.159 ± 39.2536 | 47.951 ± 42.1139 |
| Change at 2.5 Hours Post TAK-653 Dose: SICI 2 ms | 5.052 ± 47.5676 | 1.772 ± 35.9158 | -14.580 ± 37.7311 |
| Baseline: SICI 5 ms | 70.640 ± 49.8699 | 59.672 ± 37.7419 | 72.722 ± 62.0484 |
| Change at 2.5 Hours Post TAK-653 Dose: SICI 5 ms | 14.303 ± 81.6111 | 4.274 ± 30.8966 | -7.247 ± 52.9205 |
The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg/kg Ketamine.
| percentage of maximum stimulator output | Ketamine 0.5 mg/kg |
|---|---|
| Baseline | 54.4 ± 9.28 |
| Change at 2.5 hours Ketamine Post Dose | 0.7 ± 4.18 |
| Change at 24 hours Ketamine Post Dose | 0.8 ± 3.10 |
TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment 0.5 mg/kg Ketamine.
| mcV | Ketamine 0.5 mg/kg |
|---|---|
| Baseline | 1150.618 ± 1047.3920 |
| Change at 2.5 hours Ketamine Post Dose | -193.897 ± 897.0245 |
| Change at 24 hours Ketamine Post Dose | -295.041 ± 944.4889 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug until 14 days after last dose in Treatment Period 4 (up to Day 48). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/24 (0%) | 0/24 (0%) | 7/24 (29.2%) |
| TAK-653 0.5 mg | 0/24 (0%) | 0/24 (0%) | 9/24 (37.5%) |
| TAK-653 6 mg | 0/24 (0%) | 0/24 (0%) | 12/24 (50%) |
| Ketamine 0.5 mg/kg | 0/20 (0%) | 0/20 (0%) | 20/20 (100%) |
| Event | Placebo | TAK-653 0.5 mg | TAK-653 6 mg | Ketamine 0.5 mg/kg |
|---|---|---|---|---|
| DissociationPsychiatric disorders | 0/24 | 0/24 | 0/24 | 15/20 |
| DizzinessNervous system disorders | 1/24 | 0/24 | 1/24 | 8/20 |
| NauseaGastrointestinal disorders | 1/24 | 0/24 | 1/24 | 5/20 |
| HeadacheNervous system disorders | 2/24 | 1/24 | 4/24 | 3/20 |
| SomnolenceNervous system disorders | 2/24 | 3/24 | 3/24 | 3/20 |
| NasopharyngitisInfections and infestations | 0/24 | 3/24 | 1/24 | 0/20 |
| Dry MouthGastrointestinal disorders | 0/24 | 0/24 | 0/24 | 2/20 |
| Feeling ColdGeneral disorders | 0/24 | 0/24 | 0/24 | 2/20 |
| Feeling DrunkGeneral disorders | 0/24 | 0/24 | 0/24 | 2/20 |
| Vision BlurredEye disorders | 0/24 | 0/24 | 0/24 | 2/20 |
The safety analysis set included all participants who were randomized and received at least 1 dose of study drug. Baseline characteristics data has been presented for overall participants analyzed.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 27.9 ± 9.0 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 1 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 22 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| Netherlands | 24 |
| Weight(kilogram (Kg)) | All Participants |
|---|---|
| Mean | 79.12 ± 10.81 |
| Height(centimeter (cm)) | All Participants |
|---|---|
| Mean | 181.98 ± 9.88 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | All Participants |
|---|---|
| Mean | 23.93 ± 2.85 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2019 to primary completion in May 2019, 3 months.
Results were first posted in Jul 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osavampator